Patents Assigned to ARACLON BIOTECH, S.L.
-
Publication number: 20210214394Abstract: The invention relates to antibodies which are used in the preparation of a medicament for the treatment of Alzheimer's disease. More specifically, the invention relates to the use of an antibody specifically recognizing any one of the predominant variants of the amyloid beta peptide, A?40 and A?42, in the preparation of a medicament that is used to prevent and/or treat Alzheimer's disease.Type: ApplicationFiled: March 26, 2021Publication date: July 15, 2021Applicant: ARACLON BIOTECH, S.L.Inventor: Manuel SARASA BARRIO
-
Publication number: 20210011032Abstract: The invention relates to methods for the diagnostic of a neurodegenerative disease, for the detection of a stage prior to a neurodegenerative disease or for distinguishing neurodegenerative disease from a stage prior to a neurodegenerative disease based on the level of certain pools of amyloid beta peptides which are either bound to plasma components or bound to blood cells as well as on certain calculated parameters which are obtained by an arithmetic combination of one or more of the amyloid peptide levels. The invention relates as well to kits for carrying out the above method.Type: ApplicationFiled: August 5, 2020Publication date: January 14, 2021Applicant: ARACLON BIOTECH, S.L.Inventor: José Manuel Sarasa Barrio
-
Publication number: 20200140488Abstract: The invention relates to antibodies which are used in the preparation of a medicament for the treatment of Alzheimer's disease. More specifically, the invention relates to the use of an antibody specifically recognizing any one of the predominant variants of the amyloid beta peptide, A?40 and A?42, in the preparation of a medicament that is used to prevent and/or treat Alzheimer's disease.Type: ApplicationFiled: January 16, 2020Publication date: May 7, 2020Applicant: ARACLON BIOTECH, S.L.Inventor: Manuel SARASA BARRIO
-
Patent number: 9863961Abstract: The invention relates to the field of immunoassays which allow the detection of A? 17 peptides by virtue of the use of an anti-A? 17 antibody and a kit and method using said antibody. The invention also relates to a method for diagnosing or distinguishing between different stages of a neurodegenerative disease.Type: GrantFiled: December 22, 2015Date of Patent: January 9, 2018Assignee: ARACLON BIOTECH, S.L.Inventor: Manuel Sarasa Barrio
-
Publication number: 20160195548Abstract: The invention relates to the field of immunoassays which allow the detection of A?17 peptides by virtue of the use of an anti-A?17 antibody and a kit and method using said antibody. The invention also relates to a method for diagnosing or distinguishing between different stages of a neurodegenerative disease.Type: ApplicationFiled: December 22, 2015Publication date: July 7, 2016Applicant: ARACLON BIOTECH, S.L.Inventor: Manuel Sarasa Barrio
-
Publication number: 20140086945Abstract: The invention provides conjugates comprising albumin and a peptide derived from the C-terminal region of amyloid beta peptide, as well as uses thereof for the treatment of diseases characterized by the deposition of amyloid proteins and, in particular, for the treatment of Alzheimer's disease.Type: ApplicationFiled: September 20, 2013Publication date: March 27, 2014Applicant: ARACLON BIOTECH S.L.Inventor: J. Manuel SARASA BARRIO
-
Publication number: 20140044725Abstract: The invention relates to antibodies which are used in the preparation of a medicament for the treatment of Alzheimer's disease. More specifically, the invention relates to the use of an antibody specifically recognizing any one of the predominant variants of the amyloid beta peptide, A?40 and A?42, in the preparation of a medicament that is used to prevent and/or treat Alzheimer's disease.Type: ApplicationFiled: September 13, 2013Publication date: February 13, 2014Applicant: ARACLON BIOTECH, S.L.Inventor: MANUEL SARASA BARRIO
-
Publication number: 20140024054Abstract: The invention relates to the field of immunoassays which allow the detection of A? 17 peptides by virtue of the use of an anti-A? 17 antibody and a kit and method using said antibody. The invention also relates to a method for diagnosing or distinguishing between different stages of a neurodegenerative disease.Type: ApplicationFiled: April 3, 2012Publication date: January 23, 2014Applicant: ARACLON BIOTECH, S.L.Inventor: Manuel Sarasa Barrio
-
Publication number: 20120264642Abstract: The invention relates to methods for the diagnostic of a neurodegenerative disease, for the detection of a stage prior to a neurodegenerative disease or for distinguishing neurodegenerative disease from a stage prior to a neurodegenerative disease based on the level of certain pools of amyloid beta peptides which are either bound to plasma components or bound to blood cells as well as on certain calculated parameters which are obtained by an arithmetic combination of one or more of the amyloid peptide levels. The invention relates as well to kits for carrying out the above method.Type: ApplicationFiled: December 13, 2010Publication date: October 18, 2012Applicant: ARACLON BIOTECH, S.L.Inventor: José Manuel Sarasa Barrio
-
Publication number: 20110262458Abstract: The invention relates to antibodies which are used in the preparation of a medicament for the treatment of Alzheimer's disease. More specifically, the invention relates to the use of an antibody specifically recognizing any one of the predominant variants of the amyloid beta peptide, Ab40 and Ab42, in the preparation of a medicament that is used to prevent and/or treat Alzheimer's disease.Type: ApplicationFiled: March 17, 2011Publication date: October 27, 2011Applicant: ARACLON BIOTECH, S.L.Inventor: MANUEL SARASA BARRIO